Spyre Therapeutics Says SPY001 Part A Induction Results from Phase 2 SKYLINE Trial Met Its Primary Endpoint For Moderate-To-Severely Active Ulcerative Colitis
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score
Secondary endpoints included clinical remission by modified Mayo Score of 40% and endoscopic improvement of 51%
SPY001 was well tolerated with a safety profile consistent with the α4β7 class
Recruitment for SKYLINE Part A closed, now enrolling Part B monotherapy and combination cohorts
Login to comment